Title |
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
|
---|---|
Published in |
Applied Health Economics and Health Policy, February 2018
|
DOI | 10.1007/s40258-018-0371-0 |
Pubmed ID | |
Authors |
Don Husereau, Brian Feagan, Carl Selya-Hammer |
Abstract |
Biosimilars are becoming increasingly available internationally as patents expire on the originator biologic drugs they are intended to copy. Although substitution policies seen with generic drugs are being considered as a means to reduce expenditures on biologics, some biosimilars pose particular challenges in that the act of substitution may eventually lead to increased rates of therapeutic failure. As evidence requirements from regulators do not directly address this challenge, switch trials of biosimilars have emerged that may provide further answers. Using infliximab in inflammatory bowel disease as an example, we critically examine emerging evidence from two key switch trials (NOR-SWITCH and NCT020968610) and discuss the clinical and economic implications of these and what policy options may be most reasonable for payers. Options include reimbursing biosimilars for only newly diagnosed patients, using product-listing agreements to manage uncertainty, or using tiered co-payments or other incentives to promote biosimilar use. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 4 | 40% |
United States | 1 | 10% |
Saudi Arabia | 1 | 10% |
New Zealand | 1 | 10% |
Pakistan | 1 | 10% |
Unknown | 2 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 9 | 90% |
Science communicators (journalists, bloggers, editors) | 1 | 10% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 45 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 10 | 22% |
Researcher | 7 | 16% |
Student > Ph. D. Student | 4 | 9% |
Student > Doctoral Student | 2 | 4% |
Student > Postgraduate | 2 | 4% |
Other | 4 | 9% |
Unknown | 16 | 36% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 22% |
Medicine and Dentistry | 8 | 18% |
Computer Science | 3 | 7% |
Business, Management and Accounting | 2 | 4% |
Nursing and Health Professions | 2 | 4% |
Other | 4 | 9% |
Unknown | 16 | 36% |